Simtra BioPharma Solutions announced a $250+ million expansion
The company is allocating over $250 million towards its Bloomington, Ind. Manufacturing site.
Simtra BioPharma Solutions revealed on February 28, 2024, its plan to invest over $250 million in expanding its sterile fill/finish manufacturing campus in Bloomington, Ind. After Advent International and Warburg Pincus acquired Baxter's BioPharma Solutions business in October 2023, it now operates under Simtra BioPharma Solutions.
The new expansion will introduce a cutting-edge 150,000-square-foot building with two high-speed automated isolator syringe fill lines and a high-speed isolator vial line equipped with three 30-square-meter lyophilizers. The new building will feature process suites with dedicated formulation/compounding rooms, along with a dedicated clinical line to support the company’s development and clinical business.
Construction of the new building is anticipated to start in June 2024 and finish by late 2026. The clinical line is projected to be operational for projects by the summer of 2025, enabling the company to handle Phase I or II development projects onsite as they prepare for commercialization.
We are seeing a significant rise in demand for injectable manufacturing in therapeutic classes like GLP-1 drugs and product categories such as antibody-drug-conjugates, along with the ongoing growth of the oncology pipeline. Customers of Simtra BioPharma Solutions view their sites in Halle and Bloomington as an extension of their manufacturing network. It's exciting to improve their capabilities and resources to support their goals. This expansion is part of a series of strategic, long-term investments to ensure that Simtra continues to evolve alongside its customers.
They are thrilled to support the outstanding team at Simtra to make the initial, and hopefully, many more, significant growth investments as we establish the top, autonomous sterile injectable CDMO," stated Carmine Petrone, a managing director at Advent International, and Ruoxi Chen, a managing director at Warburg Pincus, in the announcement. The expansion has been carefully planned to cater to the requirements of our customers and their patients. We're thrilled about the business's trajectory, considering the dynamic industry backdrop, and our goal is to help Simtra's customers provide more doses of life-sustaining therapies to patients.
Simtra BioPharma Solutions specializes in injectable contract development and manufacturing services, offering GMP sterile fill/finish and development services. In 2021, the company, Baxter BioPharma Solutions, invested over $100 million to expand its Halle/Westfalen, Germany site by adding a high-speed syringe line and a vial line with four lyophilizers. The company anticipates the expansion will be GMP-ready by the end of 2024.
Source: Simtra BioPharma Solutions
